These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38093030)

  • 21. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
    Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
    Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
    Zhu Y; Liu K; Cao H; Zhu H
    J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China.
    Wei Q; Xu Y; Liu W; Guan X
    Cost Eff Resour Alloc; 2023 Nov; 21(1):91. PubMed ID: 38012661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.
    Favre-Bulle A; Huang M; Haiderali A; Bhadhuri A
    Pharmacoecon Open; 2024 Jan; 8(1):91-101. PubMed ID: 37999854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
    Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
    Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
    Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Chandiwana D; Park J; Delea TE
    Pharmacoeconomics; 2021 Jul; 39(7):853-867. PubMed ID: 34002341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.
    Younis T; Lee A; Coombes ME; Bouganim N; Becker D; Revil C; Jhuti GS
    Curr Oncol; 2020 Dec; 27(6):e578-e589. PubMed ID: 33380873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Wu B; Shi L
    J Natl Compr Canc Netw; 2020 Nov; 18(11):1528-1536. PubMed ID: 33152708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
    Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
    Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
    Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
    Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    Yong CM; Yehgambaram PAP; Lee SWH
    PLoS One; 2024; 19(2):e0298130. PubMed ID: 38300930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant Olaparib for Patients with
    Tutt ANJ; Garber JE; Kaufman B; Viale G; Fumagalli D; Rastogi P; Gelber RD; de Azambuja E; Fielding A; Balmaña J; Domchek SM; Gelmon KA; Hollingsworth SJ; Korde LA; Linderholm B; Bandos H; Senkus E; Suga JM; Shao Z; Pippas AW; Nowecki Z; Huzarski T; Ganz PA; Lucas PC; Baker N; Loibl S; McConnell R; Piccart M; Schmutzler R; Steger GG; Costantino JP; Arahmani A; Wolmark N; McFadden E; Karantza V; Lakhani SR; Yothers G; Campbell C; Geyer CE;
    N Engl J Med; 2021 Jun; 384(25):2394-2405. PubMed ID: 34081848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore.
    Lim EH; Lim A; Khara JS; Cheong J; Fong J; Sivanesan S; Griffiths M; New E; Lee SC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):413-426. PubMed ID: 38289042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Yamauchi H; Toi M; Takayama S; Nakamura S; Takano T; Cui K; Campbell C; De Vos L; Geyer C; Tutt A
    Breast Cancer; 2023 Jul; 30(4):596-605. PubMed ID: 37005966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
    Morganti S; Bychkovsky BL; Poorvu PD; Garrido-Castro AC; Weiss A; Block CC; Partridge AH; Curigliano G; Tung NM; Lin NU; Garber JE; Tolaney SM; Lynce F
    Oncologist; 2023 Jul; 28(7):565-574. PubMed ID: 37210568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden.
    Justo N; Wilking N; Jönsson L
    Clin Drug Investig; 2023 Jul; 43(7):529-540. PubMed ID: 37422544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.